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A B S T R A C T
Renal artery disease (RAD) is a relatively common condition in the elderly, especially 
in the setting of concomitant vascular disease in other anatomical sites and is most 
often of atheromatous origin. Rarely is it encountered in young women as a result of 
fibromuscular dysplasia. RAD with significant renal artery stenosis is considered re-
sponsible for refractory or accelerated hypertension, progressive loss of renal function 
and deterioration of patients’ cardiovascular status, with episodes of angina or pulmo-
nary edema disproportional to the extent of coronary artery disease and left ventricle 
functional capacity, dominating the clinical presentation. This article summarizes the 
pathophysiological implications and diagnostic methods and attempts a review of the 
current literature on indications and efficacy of the available therapeutic options for 
renal artery stenosis, focusing on interventional treatment.
I N T R O D U C T I O N
Renal artery disease (RAD) is most commonly due to atherosclerosis (≈90%) or 
fibromuscular dysplasia (10%) and rarely to extrinsic compression, neurofibromatosis 
type I or Williams syndrome. Fibromuscular dysplasia (FMD) predominates in young 
women (30-50 years old), is a nonatherosclerotic, noninflammatory vascular disease that 
causes stenosis in medium and small arteries, most commonly involving the distal 2/3 
of the renal artery and carotid arteries. Atherosclerotic renal artery stenosis is usually 
encountered in males over 55 years old and often occurs at the ostium or the proximal 
2 cm of the artery.1,2 Refractory hypertension, progressive renal function deterioration 
and recurrent episodes of decompensated heart failure or flash pulmonary oedema 
are the most common clinical manifestations of the disease.1 Both conservative and 
interventional treatment has been proposed and applied with comparable efficacy in 
the case of atherosclerotic disease and thus certain controversies have arisen regarding 
the treatment of choice.3
E p I D E m I O l O g y
The true epidemiology of RAD is less well-known,4 because the majority of such 
data are derived from studies of patients undergoing other procedures, mainly cardiac 
catheterization. The prevalence of RAD in the elderly has been reported to be 6.8%. 
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In individuals with coronary heart disease, RAD coexists in 
15-23% and in cases of aortoiliac or lower extremity vascular 
disease, it is found in 28-38% and 45-59% respectively.4-7 In 
the most extensive study so far,4,8 11% of patients undergoing 
cardiac catheterization had greater than 50% unilateral nar-
rowing of the renal artery, 2.4% had bilateral 50-75% and 16% 
had >75% bilateral stenoses. In this study the severity of the 
disease was predicted by old age, gender, peripheral vascular 
disease, congestive heart failure, renal insufficiency, smoking 
and the degree of coronary artery involvement.
C l I N I C A l  I m p l I C A T I O N S
Renal artery disease has two cardinal pathophysiological 
consequences. A) It leads to renin-angiotensin-aldosterone 
system activation [in unilateral (Goldblatt) stenosis] and B) 
reduces glomerular filtration and salt and water extraction 
(bilateral artery stenosis or stenosis of the renal artery of a 
solitary kidney). Most patients remain clinically asymptom-
atic due to the large kidney functional reserve. Incidental 
RAD is usually identified during imaging of other vessels, i.e. 
while performing coronary or peripheral vessel angiography. 
Hypertension usually with abrupt onset in persons <30 years 
of age could be a manifestation of fibromuscular dysplasia. If 
the diagnosis is first made in the age over 50, atherosclerotic 
RAD should be considered. Accelerated, malignant or resis-
tant hypertension should point the diagnostic view towards 
RAD.1,4 Patients developing progressive renal failure which 
may be ischemic or drug induced (administration of ACEI 
or ARBs), as well as unexplained hypokalemia (secondary 
aldosteronism), ought to be examined for RAD. The presence 
of flank bruit or atherosclerotic disease elsewhere in the body 
may be supportive findings. Kidney size is also an important 
parameter. It has been reported that 71% of patients with 
an atrophic kidney (length <7cm) have severe stenosis of 
the renal artery ipsilateral to the small kidney.1 Three stud-
ies have shown that, if a discrepancy in size between the 2 
kidneys of greater than 1.5 cm exists, there is a 60% chance 
that the contralateral renal artery (normal sized kidney) is 
severely stenotic.1,9 Finally, recurrent episodes of congestive 
heart failure and flash pulmonary edema, in the absence of 
significant myocardial ischemia or impaired left ventricular 
systolic function can result from bilateral renal artery stenoses 
or unilateral to a single functioning kidney.1,9,10 Tables 1 and 2 
summarize the clinical manifestations of the disease.
D I A g N O S I S
Both imaging and functional assessment has been used 
in RAD evaluation. In cases of high clinical suspicion an im-
aging modality should be employed. Captopril renography, 
duplex ultrasonography of the renal arteries, spiral computed 
tomography with angiography (CTA), gadolinium magnetic 
resonance angiography (MRA) and contrast arteriography have 
been used (Table 3).
C A p T O p R I l  R E N O g R A p h y
Captopril (or other ACEIs) magnifies the functional dif-
ference between kidneys reducing glomerular filtration rate 
(GFR) by 30% in the kidney with the stenotic artery. This leads 
to accumulation of radionuclide in the affected kidney. The 
test provides an indirect assessment of renal blood supply and 
presents a sensitivity of 85-90% and specificity of 93%, providing 
TABlE1. Clinical Manifestations of Renal Artery Stenosis




TABlE 2. Clinical Clues to the Diagnosis of Atherosclerotic 
Renal Artery Stenosis
• Onset of hypertension after the age of 55
• Exacerbation of previously well-controlled hypertension
• Malignant hypertension
• Resistant hypertension
• Epigastric bruit (systolic/diastolic)
• Unexplained azotemia
• Azotemia while receiving angiotensin-converting enzyme in-
hibitors or angiotensin receptor blocking agents
• Atrophic kidney or discrepancy in size between the two kidneys
• Recurrent congestive heart failure or “flash” pulmonary edema
• Atherosclerosis elsewhere
TABlE 3. Diagnostic Modalities Used to Diagnose Renal 
Artery Stenosis
Test Sensitivity (%) Specificity (%)
Captopril scan 85–90 90




CT = computed tomography; MRA = magnetic resonance angiog-
raphy; MRI = magnetic resonance imaging
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that one of the kidneys is normal. The presence of renal insuf-
ficiency (creatinine ≥2mg/dl) or bilateral renal artery stenoses 
severely influences the test’s accuracy raising the likelihood of 
false positive scans.1,10-12
D O p p l E R  U l T R A S O U N D
Doppler ultrasound of the renal arteries allows reliable serial 
estimation of flow velocities. A rise in velocity to more than 
200 cm/sec or to a value higher than the aortic velocities with 
renal-aortic ratio ≥3.5 is considered predictive of more than 
60% luminal narrowing.1,10,13,14 Assessment of post-stenotic 
blood flow and vascular resistance within the kidney (resistive 
index) provides a guide to the potential salvageability of the 
kidney and the likelihood of blood pressure response post-
interventionally. The method exhibits an 84-98% sensitivity and 
62-99% specificity, is safe and cost-effective. However, it does 
not provide us with any functional assessment of the kidney, the 
method is technically demanding and time-consuming, some 
individuals are not suitable for the study and accessory renal 
arteries cannot be reliably identified.
C T  A N g I O g R A p h y
CT angiography (CTA) has an 89-100% sensitivity and 
82-100% specificity.10,15,16 Because it requires large amounts of 
nephrotoxic contrast medium, its use in azotemic patients is 
limited. Gadolinium contrast MRA provides visualization of 
the main renal arteries with high sensitivity (91-100%) and 
specificity (76-94%), and offers the most complete non-invasive 
imaging of the renal vasculature with a nonnephrotoxic agent. 
It is limited by cost, availability and by the fact that it may miss 
distal vascular lesions or accessory vessels.
C O N T R A S T  A R T E R I O g R A p h y
Contrast arteriography still remains the “gold standard” for 
diagnosing RAD, performed at the time of planned endovas-
cular intervention (balloon angioplasty or stent deployment). 
The hazards include atheroembolic disease and contrast ne-
phrotoxicity especially in older or diabetic patients. The use of 
non-toxic agents such as gadolinium or carbon dioxide may be 
beneficial in cases of renal insufficiency.10,12
Functional tests are used to establish whether a) hemo-
dynamically significant lesions impair blood flow or activate 
renin release and b) correction of the vascular lesion can 
produce improvement in blood flow or renal function. They 
include plasma renin activity (PRA), captopril stimulated PRA, 
renal vein renin activity, intravenous pyelography, iodine-125 
diethylenetriaminepenta-acetic acid (DTPA) scan (glomerular 
filtration assessment), captopril renography with Tc-mercap-
totriglycylglycine, radionuclide scan with Tc 99m (renal blood 
flow assessment). These tests require comparison of a stenotic 
kidney with a presumed normal contralateral kidney, which 
is often actually abnormal. 10,17 Furthermore, indices of renal 
function (creatinine >3 mg/dl) and proteinuria are important 
in predicting recovery of kidney function after surgical or 
endovascular repair. 12
T R E A T m E N T
Treatment decisions for the management of RAD should 
consider relative benefits and risks involved and must take 
into account the likelihood of blood pressure reduction and 
renal parenchyma preservation. In general, medical therapy is 
considered in cases of underlying advanced nephropathy with 
unilateral RAD and creatinine >2.5 mg/dl, renal length <7 
cm, proteinuria >1 g/day, severe diffuse intrarenal disease and 
target kidney resistive index >80. Medical therapy includes 
antihypertensive, cholesterol-lowering and antiplatelet drugs. 
ACEIs, ARBs, calcium channel blockers and β-blockers are 
commonly used with proven efficacy and safety. However, 
a potential consequence of conservative therapy is disease 
progression as reported by small series,18-20 potentially leading 
to renal artery occlusion, which makes even the endovascular 
therapy extremely difficult. Another consideration would be 
the possibility of progressively worsening renal function, lead-
ing to end-stage renal disease. Interestingly, a retrospective 
cohort evaluation suggests that serum creatinine levels remain 
stable for many years,18,21 but the small numbers of patients 
observed makes it hard to base real clinical management deci-
sions on such reports.
Revascularization is favoured in patients with bilateral 
renal artery stenoses and creatinine >1.5 mg/dl, unilateral 
renal artery stenosis and fractional glomerular filtration rate 
<40%, ACEI-induced renal failure, hypertensive crisis and 
non-ischemic pulmonary edema (Table 3).10 Revascularization 
can be attempted by intraluminal intervention or surgery. The 
surgical techniques include aortorenal, hepatorenal or spleno-
renal by-pass.22,23 Nowadays, medical and endovascular meth-
ods have become more established, but surgery still retains a 
role. Current indications for surgical revascularisation include: 
occluded renal artery with preserved renal parenchyma, RAD 
with Takayasu’s arteritis, RAD with multiple small renal arter-
ies or early primary branching of the main renal artery, branch 
disease from FMD that cannot be treated adequately with 
balloon angioplasty, especially in patients exhibiting complex 
disease that extends into the segmental arteries and those 
TABlE 4. Indications for  Renal Artery Revascularization
≥50% stenosis





HOSPITAL CHRONICLES 4(2), 2009
having macro-aneurysms, recurrent stenosis after stenting 
or simultaneous aortic surgery (abdominal aortic aneurysm 
repair or symptomatic aortoiliac disease). Even in this last 
circumstance, it may be advisable to stent the renal artery first 
and then proceed with aortic reconstruction. The mortality 
rate of aortic replacement and renal artery revascularisation 
is higher than for either procedure alone.22
Current recommendations (ACC/AHA) for renal artery 
revascularization include:
 • Asymptomatic RAD in case of bilateral or solitary viable 
kidney with a hemodynamically significant renal artery 
stenosis (class IIb, LOE C).
 • Accelerated hypertension, resistant hypertension, ma-
lignant hypertension, hypertension with an unexplained 
unilateral small kidney, and hypertension with intolerance 
to medication in patients with hemodynamically significant 
renal artery stenosis (class IIa, LOE B).
 • Progressive chronic kidney disease with bilateral renal 
artery stenoses or a renal artery stenosis in a solitary 
functioning kidney (class IIa, LOE B).
 • RAD and chronic renal insufficiency with unilateral renal 
artery stenosis (class IIb, LOE C).
 • Hemodynamically significant RAD and recurrent, unex-
plained congestive heart failure or sudden, unexplained 
pulmonary edema (class I, LOE B).
 • Hemodynamically significant RAD and unstable angina 
(class IIa, LOE B).24
Single balloon angioplasty is the treatment of choice in 
fibromuscular dysplasia. However in atherosclerotic lesions, 
stent placement is indicated in order to minimize the risk of 
procedure failure and the restenosis rate. Van de Ven et al. 
performed a trial in 1999 comparing 42 patients undergoing 
renal artery angioplasty with 45 patients receiving angioplasty 
and stenting. They found that success as well as patency rates 
were significantly higher in the second group although the dif-
ferencies in renal function or blood pressure were stasistically 
non significant. Similar results were reported by Rundback 
et al.25,26
T E C h N I q U E  O f  p E R C U T A N E O U S 
T R A N S l U m I N A l  R E N A l  A N g I O p l A S T y 
( p T R A )  A N D  S T E N T I N g
Until the beginning of the 1990s, balloon angioplasty was 
the only method of percutaneous treatment of renal artery ste-
nosis with satisfying acute and long-term results for angioplasty 
of stenoses caused by FMD and atherosclerotic stenosis of the 
renal artery trunk.27-29 However, balloon angioplasty of ostial 
atherosclerotic lesions was limited by a low acute technical suc-
cess rate (50–62%) and a high restenosis rate of up to 47% over 
the long-term because of the potential for dissection and elastic 
recoil or rigidity of the lesion.30 The introduction of stenting has 
revolutionized percutaneous renal revascularization. Follow-
ing promising single center reports,31,32 two randomized studies 
proved the superiority of stenting over conventional balloon 
angioplasty25,33 in the treatment of atherosclerotic ostial renal 
artery stenosis, the most common manifestation of renal artery 
stenosis. Nowadays using premounted low profile stent devices 
(“nested ring design”), atherosclerotic renal artery stenosis can 
be successfully treated in almost 100% of cases with restenosis 
rates ranging from 0% to 23% depending on the diameter of 
the renal artery.29,34
Currently, the guiding catheter technique is the proce-
dure of choice with the lowest intervention and radiation 
time. Selective catheterization of the renal artery is usually 
performed through the guiding catheter using a steerable 
0.014 or 0.018 inch stiff guidewire with a flexible tip. Except 
in case of subtotal occlusion, direct stenting is feasible in 
almost all cases of ostial renal artery stenosis using the new 
flexible low profile stent devices. In rare cases of unfavorable 
anatomy, the brachial approach is a reliable alternative. An 
alternative technique is the use of a guiding sheath or long 
preshaped sheath; this device (e.g., Vista Britetip IG, Cordis 
Corp., Miami, FL, USA) combines the traditional sheath with 
a guiding catheter. Adverse events reported in angioplasty 
studies included death by 30 days in up to 3% of patients, 
transient deterioration of kidney function in 1% to 13%, renal 
artery or parenchymal injury in up to 5%, and peri-procedural 
cardiovascular events in up to 3%. Other adverse events that 
have been reported are hemorrhage, hematomas, and renal 
artery occlusion. Seventeen studies of angioplasty with stent 
placement showed restenosis rates that ranged from 10% to 
21% during follow-up of 3 to 40 months.35-37
The main causes of renal function deterioration after the 
procedure are embolism and contrast-induced nephropathy. 
To avoid renal embolism prior to selective renal angiogra-
phy, the guiding catheter should be cleaned from debris by 
aspiration of blood through the gu iding catheter (“proximal 
protection”). This technique cleans the tip of the guiding 
catheter from debris collected during the engagement of the 
renal artery and therefore reduces the risk of renal emboli-
zation. The use of distal protection devices is limited by the 
anatomy of the renal artery, 29 but recently there have been 
reports about the use of such devices in renal intervention.38 To 
avoid contrast-induced nephropathy, nowadays carbon dioxide 
or gadodiamide can be used as alternative contrast agents if 
digital subtraction technique is available.39,40 Furthermore, 
the development of less nephrotoxic contrast agents such as 
iodixanol (an iso-osmolar, nonionic-iodinated contrast agent), 
nephroprotective agents, and pre- and post-interventional 
hydration of the patient have also led to a reduction of the 
frequency of contrast nephropathy.29
Another future development is the use of drug-eluting 
stents for renal application. The GREAT trial found that the 
blood pressure and angiographic outcome at 6 months did not 
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show a significant difference between bare metal and sirolimus 
eluting stents, but the small number of patients examined 
may have influenced the results.41 Thus, future studies with a 
larger patient population and longer angiographic follow-up 
are warranted to determine if there is a significant benefit 
of drug-eluting stents in treating ostial renal artery stenosis. 
However, an increased restenosis rate is only a matter of 
concern in small renal arteries with a diameter of 5 mm or 
less,42 and drug-eluting stents may be indicated only for these 
vessels. Lower rates of mortality, stroke, myocardial infarction 
and azotemia, and better blood pressure control have been 
reported in patients receiving renal artery stenting compared to 
those treated only medically (87% 5-year survival vs 67%).30,43 
However, two recent studies (DRASTIC, Scottish) failed to 
prove the superiority of interventional treatment. The Scot-
tish study was unable to demonstrate any benefit with respect 
to renal function or event-free survival. The DRASTIC study 
concluded that angioplasty has little advantage over medical 
therapy in individuals with hypertension and RAD, but the 
crossover of patients between the medical and angioplasty 
group was high so that the results are considered virtually 
uninterpretable.19,20,44
So far the available evidence is neither adequate nor suf-
ficiently applicable to current practice to clearly support one 
treatment approach over another for the general population 
with RAD. Blood pressure (classified as cured, improved 
or unchanged) can be decreased adequately with combina-
tion antihypertensive medication but intervention may lead 
to better control, particularly in cases of bilateral vascular 
disease. Both medical and interventional approaches lower 
it, but almost all angioplasty studies report that some persons 
(≈18%) were cured of hypertension.29,35 However, randomized 
studies regarding blood pressure control are seriously flawed. 
Although most practitioners consider significant a stenosis 
over 70%, the studies incorporated patients with stenosis 
>50%, which notably is consistent with the latest guidelines 
published by the American College of Cardiology (ACC). 
Crossover between persons randomized in the angioplasty 
or conservative branch3,19 in two studies, makes their results 
rather confusing, neither supporting nor refuting the potential 
benefits of revascularization.
Most studies suggest no large differences in mortality rates, 
cardiovascular events or change in kidney function between 
patients treated only medically and those receiving angio-
plasty. Within the published studies of angioplasty, 8-51% of 
patients improved their kidney function, while approximately 
31% worsened it.35
The existing trials so far have also failed to demonstrate 
hard evidence on kidney function improvement with either 
conventional or invasive therapy.3 It is a fact that there is 
poor correlation between the degree of anatomic stenosis 
and glomerular filtration rate. Nuclear studies have shown 
that GFR in the non stenotic kidney is often the same or even 
lower than that in the kidney distal to a stenosis.3,33 This phe-
nomenon probably relates to the presence of ischemic damage 
in the post stenotic kidney and hypertensive injury to the non 
stenotic one, which also explains why filtration rate often fails 
to improve significantly after revascularization. Observational 
studies report that kidney function may stabilize or get better 
in some individuals. On the other hand, interventional therapy 
may itself cause declines in renal function either from contrast 
nephropathy or atheroembolic disease (Table 5). In a largest 
prospective randomized trial, there was no difference in kidney 
function in the two groups of patients one year later.3
Another clinical condition associated with RAD as already 
mentioned, is flash pulmonary edema. There are studies dem-
onstrating decline of hospitalization for such reasons after 
renal artery stenting and NyHA class improvement, but the 
concomitant increase in the use of ACEI observed during the 
study may have contributed to the improved outcome.3,36 The 
Scottish and Newcastle Renal Artery Stenosis Collaborative 
Group found no differences in event rates for congestive heart 
failure, stroke or myocardial infarction across 54 months of 
follow –up between the two groups.20,35 Studies commenting 
on survival were generally too small to detect anything but 
large differences in mortality rates, and no large differences 
in mortality rates were found. Mortality rates greater than 
40% within 6 years occurred mostly in studies of patients with 
high-grade stenosis (>75%) or bilateral disease.35 Ischemic 
nephropathy is an important cause of end-stage disease and 
among patients who are receiving dialysis, those with reno-
vascular disease have the lowest survival rate with a median 
TABlE 5. Complications of PTRA ± Renal Artery Stenting
local renal (3–83%)
1. Contrast-induced acute renal failure (mild or severe)
2. Atheroembolic renal failure (0.5%)
3. Rupture of the renal artery
4. Dissection of the renal artery
5. Thrombotic occlusion of the renal artery (2%)
6. Occlusion of a branch renal artery (0.5%)
7. Balloon rupture or malfunction (may lead to inability to remove 
the balloon)
8. Renal artery spasm
puncture site
1. Hematoma, hemorrhage or vessel tear (3–48%)
2. Brachial plexus compression (axillary approach)
3. Pseudoaneurysm (0.5%)
4. Arterio-venous fistula (0.1%)
PTRA = percutaneous transluminal renal artery angioplasty
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survival of 25–34 months and a 5-year mortality rate of more 
than 80%. Left ventricular dysfunction, age, and a baseline 
creatinine level of more than 2.5 mg/dL are reported to be 
independent predictors of mortality.29 The cause of death was 
congestive heart failure or myocardial infarction (73%), stroke 
(13.5%), and malignant disease (13.5%).12
In general, the existing data cannot establish the necessity 
for angioplasty in patients fullfilling the so far accepted indica-
tions without endorsement of additional criteria. Obviously 
some of them benefit from the interventional procedure while 
others do not or even experience deterioration of their clini-
cal or laboratory status. The studies of diagnostic tests were 
inadequate to determine whether any such test may predict 
long-term outcome or guide best treatment approaches. 
Weak evidence suggests that patients with bilateral disease 
may preferentially benefit from angioplasty over medical 
treatment. Clinical symptoms and signs or laboratory values 
can also serve as predictive factors. Impaired kidney function 
predicts a higher mortality rate, poorer clinical outcomes 
including cardiovascular events and worse blood pressure 
control. On the other hand prior cardiovascular disease cor-
relates with increased mortality rates and worsening renal 
function.19,20,35-37,45-47
Among the published studies four diagnostic tests have 
been evaluated to determine their value in predicting treat-
ment outcomes in RAD. The DRASTIC study found that 
neither captopril test nor renography can predict kidney 
function or blood pressure control after treatment.35,45 Two 
cohort studies evaluated the role of baseline resistive index of 
>80%. In the first one, people with elevated resistive index 
were most likely to benefit after angioplasty and stenting in 
terms of blood pressure and renal function, while in the second 
the same individuals were more likely to have worsening renal 
function and poorer blood pressure control after angioplasty 
with or without stenting.48,49 Another study reported that non 
spiral flow on MRA predicts significantly worse kidney func-
tion outcomes.50
What becomes evident from this discussion is that until 
now there are no undoubted evidence to either prove in-
terventional approach’s superiority compared to medical 
therapy or determine the subgroup of patients which is likely 
to benefit from one or the other treatment option. More 
large randomized prospective controlled trials are needed in 
order to provide hard evidence on these controversial issues. 
Three ongoing studies are expected to enlighten this field. The 
CORAL and the STAR studies are comparing the effects of 
PTRA with stent placement and optimal medical therapy, to 
medical therapy alone on a composite end-point of adverse 
cardiovascular and renal events.51,52 The 3R study aims at 
comparing the effect of endovascular revascularization versus 
medical therapy in 300 patients.53 Their results will probably 
address many of the deficiencies in current evidence about 
revascularization and medical treatment comparison and may 
provide useful information on the value of different diagnostic 
tests on determining which therapeutic method is best for 
individual patients. However, more studies are necessary to 
avoid a spontaneous generalization of those trials’ results, 
which may lead to inappropriate treatment, misallocated 
resources and worse outcomes in case that these finding be 
applied to patients with different characteristics from those 
incorporated in the studies.
C O N C l U S I O N S
RAD is a rather common condition that threatens the 
quality of life as well as the survival of patients. The thera-
pies endorsed so far are of no undoubted effectiveness and 
interventional approach may hold advantage for certain suit-
able individuals although the existing evidence is not enough 
to establish this fact. Renal artery stenting is a particularly 
promising revascularization technique but further studies are 
needed to prove its superiority over medical treatment alone. 
The aim of the clinician must therefore be the primary and 
secondary prevention of renal atherosclerosis, the achievement 
of an earlier diagnosis and the selection of the appropriate 
treatment (conservative vs interventional) considering the 
overall prognosis of the patient.
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